Literature DB >> 1463770

Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis.

S Baba1, T Takahashi, T Kasama, H Shirasawa.   

Abstract

Amyloid A protein (AA), the major fibril protein in AA-amyloidosis, is an N-terminal cleavage product of the precursor protein, serum amyloid A (SAA). Using mass spectrometry and amino-acid sequencing, we identified and characterized two novel AA protein subsets co-deposited as amyloid fibrils in an patient having AA-amyloidosis associated with rheumatoid arthritis. One of the AA proteins corresponded to positions 2-76 (or 75) of SAA2 alpha and the other corresponded to positions 2-76 (or 75) of known SAA1 subsets, except for position 52 or 57, where SAA1 alpha has valine and alanine and SAA1 beta has alanine and valine in position 52 and 57, respectively, whereas the AA protein had alanine at the both positions. Our findings (1), demonstrate that not only one but two SAA subsets could be deposited together as an AA-amyloid in a single individual and (2), support the existence of a novel SAA1 allotype, i.e., SAA152,57Ala.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463770     DOI: 10.1016/0925-4439(92)90068-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.

Authors:  C Röcken; R Menard; F Bühling; S Vöckler; J Raynes; B Stix; S Krüger; A Roessner; T Kähne
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

2.  Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects.

Authors:  Myrna Medlej-Hashim; Valérie Delague; Eliane Chouery; Nabiha Salem; Mohammed Rawashdeh; Gérard Lefranc; Jacques Loiselet; André Mégarbané
Journal:  BMC Med Genet       Date:  2004-02-10       Impact factor: 2.103

3.  Endogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils through Different Receptors.

Authors:  Karin Christenson; Lena Björkman; Sofie Ahlin; Maja Olsson; Kajsa Sjöholm; Anna Karlsson; Johan Bylund
Journal:  Front Immunol       Date:  2013-04-22       Impact factor: 7.561

4.  Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.

Authors:  Mieke Gouwy; Mieke De Buck; Sara Abouelasrar Salama; Jennifer Vandooren; Sofie Knoops; Noëmie Pörtner; Lotte Vanbrabant; Nele Berghmans; Ghislain Opdenakker; Paul Proost; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

5.  Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.

Authors:  G B Sigal; M R Segal; A Mathew; L Jarlsberg; M Wang; S Barbero; N Small; K Haynesworth; J L Davis; M Weiner; W C Whitworth; J Jacobs; J Schorey; D M Lewinsohn; P Nahid
Journal:  EBioMedicine       Date:  2017-10-24       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.